{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,29]],"date-time":"2026-08-29T09:51:10Z","timestamp":1787997070711,"version":"build-2784847793"},"reference-count":112,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,2,9]],"date-time":"2026-02-09T00:00:00Z","timestamp":1770595200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100002738","name":"Assistance Publique - Hopitaux de Paris","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002738","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Immunology Letters"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.imlet.2026.107148","type":"journal-article","created":{"date-parts":[[2026,2,7]],"date-time":"2026-02-07T07:37:21Z","timestamp":1770449841000},"page":"107148","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Complement involvement in antiphospholipid syndrome"],"prefix":"10.1016","volume":"279","author":[{"given":"Houcine","family":"Hamidi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3210-2821","authenticated-orcid":false,"given":"Luc","family":"Darnige","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5809-8122","authenticated-orcid":false,"given":"Marie-Agn\u00e8s","family":"Dragon Durey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.imlet.2026.107148_bib0001","first-page":"1088","article-title":"Thrombosis, abortion, cerebral disease, and the lupus anticoagulant","volume":"287","author":"Hughes","year":"1983","journal-title":"Br. Med. J. Clin. Res. Ed"},{"key":"10.1016\/j.imlet.2026.107148_bib0002","doi-asserted-by":"crossref","DOI":"10.1016\/j.autrev.2022.103060","article-title":"Drug-induced antiphospholipid syndrome: Analysis of the WHO international database","volume":"21","author":"G\u00e9rardin","year":"2022","journal-title":"Autoimmun. Rev."},{"key":"10.1016\/j.imlet.2026.107148_bib0003","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1053\/sarh.2002.28303","article-title":"Viral infections and antiphospholipid antibodies","volume":"31","author":"Uthman","year":"2002","journal-title":"Semin. Arthritis Rheum."},{"key":"10.1016\/j.imlet.2026.107148_bib0004","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/0090-1229(86)90046-2","article-title":"Anticardiolipin response in acute infections","volume":"41","author":"Vaarala","year":"1986","journal-title":"Clin. Immunol. Immunopathol."},{"key":"10.1016\/j.imlet.2026.107148_bib0005","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1191\/096120399678841034","article-title":"Hughes syndrome associated with cytomegalovirus infection","volume":"8","author":"Uthman","year":"1999","journal-title":"Lupus"},{"key":"10.1016\/j.imlet.2026.107148_bib0006","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1136\/ard-2023-224609","article-title":"2023 ACR\/EULAR antiphospholipid syndrome classification criteria","volume":"82","author":"Barbhaiya","year":"2023","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.imlet.2026.107148_bib0007","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1007\/s11926-003-0031-7","article-title":"Catastrophic antiphospholipid syndrome","volume":"5","author":"Asherson","year":"2003","journal-title":"Curr. Rheumatol. Rep."},{"key":"10.1016\/j.imlet.2026.107148_bib0008","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1024\/0301-1526\/a000723","article-title":"Antiphospholipid syndrome - an update","volume":"47","author":"Linnemann","year":"2018","journal-title":"VASA Z. Gefasskrankheiten"},{"key":"10.1016\/j.imlet.2026.107148_bib0009","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1006\/jaut.2000.0409","article-title":"Epidemiology of the antiphospholipid antibody syndrome","volume":"15","author":"Petri","year":"2000","journal-title":"J. Autoimmun."},{"key":"10.1016\/j.imlet.2026.107148_bib0010","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1016\/j.revmed.2023.08.004","article-title":"Collaborators, French National Diagnostic and Care Protocol for antiphospholipid syndrome in adults and children","volume":"44","author":"Amoura","year":"2023","journal-title":"Rev. Med. Interne"},{"key":"10.1016\/j.imlet.2026.107148_bib0011","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1177\/0961203312440059","article-title":"Thrombin generation in antiphospholipid syndrome","volume":"21","author":"Zuily","year":"2012","journal-title":"Lupus"},{"key":"10.1016\/j.imlet.2026.107148_bib0012","doi-asserted-by":"crossref","first-page":"2317","DOI":"10.1016\/j.jacc.2017.02.058","article-title":"Antiphospholipid syndrome: role of vascular endothelial cells and implications for risk stratification and targeted therapeutics","volume":"69","author":"Corban","year":"2017","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.imlet.2026.107148_bib0013","doi-asserted-by":"crossref","first-page":"2140","DOI":"10.1016\/j.immuni.2024.08.007","article-title":"Antibodies and complement are key drivers of thrombosis","volume":"57","author":"Stark","year":"2024","journal-title":"Immunity"},{"key":"10.1016\/j.imlet.2026.107148_bib0014","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1007\/s11926-007-0033-y","article-title":"Role of complement in antiphospholipid antibody-mediated thrombosis","volume":"9","author":"O\u2019Neil","year":"2007","journal-title":"Curr. Rheumatol. Rep."},{"key":"10.1016\/j.imlet.2026.107148_bib0015","doi-asserted-by":"crossref","first-page":"567","DOI":"10.3389\/fimmu.2016.00567","article-title":"Analysis of the Interaction between Globular Head Modules of Human C1q and Its Candidate Receptor gC1qR","volume":"7","author":"Pednekar","year":"2016","journal-title":"Front. Immunol."},{"key":"10.1016\/j.imlet.2026.107148_bib0016","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1007\/978-3-031-85340-1_7","article-title":"The complement system","volume":"1476","author":"Revel","year":"2025","journal-title":"Adv. Exp. Med. Biol."},{"key":"10.1016\/j.imlet.2026.107148_bib0017","first-page":"71","article-title":"Interaction between the coagulation and complement system","volume":"632","author":"Amara","year":"2008","journal-title":"Adv. Exp. Med. Biol."},{"key":"10.1016\/j.imlet.2026.107148_bib0018","doi-asserted-by":"crossref","first-page":"2774","DOI":"10.1182\/blood-2011-02-339564","article-title":"\u03b2\u2082-glycoprotein I, the major target in antiphospholipid syndrome, is a special human complement regulator","volume":"118","author":"Gropp","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.imlet.2026.107148_bib0019","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.4049\/jimmunol.2000570","article-title":"Complement activation and thrombin generation by MBL bound to \u03b22-Glycoprotein I","volume":"205","author":"Durigutto","year":"2020","journal-title":"J. Immunol."},{"key":"10.1016\/j.imlet.2026.107148_bib0020","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1056\/NEJMoa0810739","article-title":"Thrombomodulin mutations in atypical hemolytic-uremic syndrome","volume":"361","author":"Delvaeye","year":"2009","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.imlet.2026.107148_bib0021","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1002\/art.10304","article-title":"Immunization of naive BALB\/c mice with human \u03b22-Glycoprotein I breaks tolerance to the murine molecule","volume":"46","author":"Tincani","year":"2002","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.imlet.2026.107148_bib0022","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1177\/096120339600500524","article-title":"In vivo models of thrombosis for the antiphospholipid syndrome","volume":"5","author":"Pierangeli","year":"1996","journal-title":"Lupus"},{"key":"10.1016\/j.imlet.2026.107148_bib0023","doi-asserted-by":"crossref","first-page":"2120","DOI":"10.1002\/art.21157","article-title":"Requirement of activation of complement C3 and C5 for antiphospholipid antibody-mediated thrombophilia","volume":"52","author":"Pierangeli","year":"2005","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.imlet.2026.107148_bib0024","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.1177\/0961203312458839","article-title":"C6 knock-out mice are protected from thrombophilia mediated by antiphospholipid antibodies","volume":"21","author":"Carrera-Mar\u00edn","year":"2012","journal-title":"Lupus"},{"key":"10.1016\/j.imlet.2026.107148_bib0025","doi-asserted-by":"crossref","first-page":"2340","DOI":"10.1182\/blood-2005-03-1319","article-title":"Thrombus formation induced by antibodies to beta2-glycoprotein I is complement dependent and requires a priming factor","volume":"106","author":"Fischetti","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.imlet.2026.107148_bib0026","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1196\/annals.1422.058","article-title":"C5a receptor-deficient mice are protected from thrombophilia and endothelial cell activation induced by some antiphospholipid antibodies","volume":"1108","author":"Romay-Penabad","year":"2007","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"10.1016\/j.imlet.2026.107148_bib0027","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/S0002-9378(11)90700-5","article-title":"Immunoglobulin G fractions from patients with antiphospholipid antibodies cause fetal death in BALB\/c mice: a model for autoimmune fetal loss","volume":"163","author":"Branch","year":"1990","journal-title":"Am. J. Obstet. Gynecol."},{"key":"10.1016\/j.imlet.2026.107148_bib0028","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1084\/jem.200116116","article-title":"Complement C3 activation is required for antiphospholipid antibody-induced fetal loss","volume":"195","author":"Holers","year":"2002","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.imlet.2026.107148_bib0029","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1186\/ar1413","article-title":"Inhibition of complement activation: a novel mechanism for the protective effects of heparin in antiphospholipid antibody-induced pregnancy loss","volume":"6","author":"Girardi","year":"2004","journal-title":"Arthritis Res. Ther."},{"key":"10.1016\/j.imlet.2026.107148_bib0030","doi-asserted-by":"crossref","first-page":"2423","DOI":"10.1182\/blood-2007-01-070631","article-title":"Tissue factor: a link between C5a and neutrophil activation in antiphospholipid antibody\u2013induced fetal injury","volume":"110","author":"Redecha","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.imlet.2026.107148_bib0031","doi-asserted-by":"crossref","first-page":"1222","DOI":"10.1038\/nm1121","article-title":"Heparin prevents antiphospholipid antibody-induced fetal loss by inhibiting complement activation","volume":"10","author":"Girardi","year":"2004","journal-title":"Nat. Med."},{"key":"10.1016\/j.imlet.2026.107148_bib0032","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.molimm.2004.07.043","article-title":"A novel inhibitor of the alternative complement pathway prevents antiphospholipid antibody-induced pregnancy loss in mice","volume":"42","author":"Thurman","year":"2005","journal-title":"Mol. Immunol."},{"key":"10.1016\/j.imlet.2026.107148_bib0033","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1002\/path.2893","article-title":"Classical complement activation as a footprint for murine and human antiphospholipid antibody-induced fetal loss","volume":"225","author":"Cohen","year":"2011","journal-title":"J. Pathol."},{"key":"10.1016\/j.imlet.2026.107148_bib0034","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.clim.2019.04.005","article-title":"Pathogenic roles of anti-C1q antibodies in recurrent pregnancy loss","volume":"203","author":"Ohmura","year":"2019","journal-title":"Clin. Immunol."},{"key":"10.1016\/j.imlet.2026.107148_bib0035","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1182\/blood-2009-01-199117","article-title":"Role of tissue factor in a mouse model of thrombotic microangiopathy induced by antiphospholipid antibodies","volume":"114","author":"Seshan","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.imlet.2026.107148_bib0036","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1136\/ard.2008.090670","article-title":"Complement activation in patients with primary antiphospholipid syndrome","volume":"68","author":"Oku","year":"2009","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.imlet.2026.107148_bib0037","first-page":"524","article-title":"Binding of complement component C1q to anti-beta2 glycoprotein I antibodies from patients with antiphospholipid syndrome","volume":"48","author":"Odorczuk","year":"1999","journal-title":"Inflamm. Res. Off. J. Eur. Histamine Res. Soc. Al"},{"key":"10.1016\/j.imlet.2026.107148_bib0038","doi-asserted-by":"crossref","first-page":"671","DOI":"10.3390\/biomedicines9060671","article-title":"Low preconception complement levels are associated with adverse pregnancy outcomes in a multicenter study of 260 pregnancies in 197 women with antiphospholipid syndrome or carriers of antiphospholipid antibodies","volume":"9","author":"Nalli","year":"2021","journal-title":"Biomedicines"},{"key":"10.1016\/j.imlet.2026.107148_bib0039","doi-asserted-by":"crossref","first-page":"1849","DOI":"10.1016\/j.jtha.2023.03.024","article-title":"High plasma levels of C1-inhibitor are associated with lower risk of future venous thromboembolism","volume":"21","author":"Grover","year":"2023","journal-title":"J. Thromb. Haemost. JTH"},{"key":"10.1016\/j.imlet.2026.107148_bib0040","first-page":"e155","article-title":"Platelets and the lectin pathway of complement activation in patients with systemic lupus erythematosus or antiphospholipid syndrome","volume":"7","author":"Vils","year":"2023","journal-title":"TH Open Companion J. Thromb. Haemost."},{"key":"10.1016\/j.imlet.2026.107148_bib0041","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1160\/TH11-08-0554","article-title":"Complement activation in patients with isolated antiphospholipid antibodies or primary antiphospholipid syndrome","volume":"107","author":"Breen","year":"2012","journal-title":"Thromb. Haemost."},{"key":"10.1016\/j.imlet.2026.107148_bib0042","doi-asserted-by":"crossref","first-page":"3943","DOI":"10.1182\/blood-2023-182287","article-title":"Complement activation is increased in antiphospholipid syndrome-related ischemic stroke with higher risk features","volume":"142","author":"Tohidi-Esfahani","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.imlet.2026.107148_bib0043","first-page":"2088","article-title":"High plasma C5a and C5b-9 levels during quiescent phases are associated to severe antiphospholipid syndrome subsets","volume":"40","author":"Ruffatti","year":"2022","journal-title":"Clin. Exp. Rheumatol."},{"key":"10.1016\/j.imlet.2026.107148_bib0044","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2025.1676578","article-title":"A proteomic map of thromboinflammatory signatures in antiphospholipid syndrome: results from antiphospholipid syndrome alliance for clinical trials and international networking (APS ACTION) registry","volume":"16","author":"Pine","year":"2025","journal-title":"Front. Immunol."},{"key":"10.1016\/j.imlet.2026.107148_bib0045","first-page":"1970","article-title":"Antiphospholipid and anti-beta 2 glycoprotein I antibodies in monozygotic twin sisters","volume":"21","author":"Cevallos","year":"1994","journal-title":"J. Rheumatol."},{"key":"10.1016\/j.imlet.2026.107148_bib0046","article-title":"Relevance of inflammatory and complement activation biomarkers profiling in antiphospholipid syndrome patients outside acute thrombosis","author":"Yelnik","year":"2023","journal-title":"Clin. Exp. Rheumatol."},{"key":"10.1016\/j.imlet.2026.107148_bib0047","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2019.00773","article-title":"Blood cell-bound C4d as a marker of complement activation in patients with the antiphospholipid syndrome","volume":"10","author":"Lonati","year":"2019","journal-title":"Front. Immunol."},{"key":"10.1016\/j.imlet.2026.107148_bib0048","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1459842","article-title":"Cell-bound complement activation products in antiphospholipid antibody-positive patients without other systemic autoimmune rheumatic diseases","volume":"15","author":"Erkan","year":"2024","journal-title":"Front. Immunol."},{"key":"10.1016\/j.imlet.2026.107148_bib0049","doi-asserted-by":"crossref","DOI":"10.1002\/eji.202350832","article-title":"Autoantibodies against complement proteins in patients with antiphospholipid syndrome: prevalence and clinical associations","author":"Philip","year":"2024","journal-title":"Eur. J. Immunol."},{"key":"10.1016\/j.imlet.2026.107148_bib0050","doi-asserted-by":"crossref","first-page":"1786","DOI":"10.3899\/jrheum.150185","article-title":"Factor H autoantibodies in patients with antiphospholipid syndrome and thrombosis","volume":"42","author":"Foltyn Zadura","year":"2015","journal-title":"J. Rheumatol."},{"key":"10.1016\/j.imlet.2026.107148_bib0051","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2019.00064","article-title":"Autoantibodies against C3b\u2014functional consequences and disease relevance","volume":"10","author":"Vasilev","year":"2019","journal-title":"Front. Immunol."},{"key":"10.1016\/j.imlet.2026.107148_bib0052","doi-asserted-by":"crossref","unstructured":"S. Chauvet, R. Berthaud, M. Devriese, M. Mignotet, P. Vieira Martins, T. Robe-Rybkine, M.A. Miteva, A. Gyulkhandanyan, A. Ryckewaert, F. Louillet, E. Merieau, G. Mestrallet, C. Rousset-Rouvi\u00e8re, E. Thervet, J. Hogan, T. Ulinski, B.O. Villoutreix, L. Roumenina, O. Boyer, V. Fr\u00e9meaux-Bacchi, Anti-factor B antibodies and acute postinfectious GN in children, J. Am. Soc. Nephrol. JASN 31 (2020) 829\u2013840. https:\/\/doi.org\/10.1681\/ASN.2019080851.","DOI":"10.1681\/ASN.2019080851"},{"key":"10.1016\/j.imlet.2026.107148_bib0053","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1681\/ASN.2004050380","article-title":"Anti-Factor H autoantibodies associated with atypical hemolytic uremic syndrome","volume":"16","author":"Dragon-Durey","year":"2005","journal-title":"J. Am. Soc. Nephrol. JASN"},{"key":"10.1016\/j.imlet.2026.107148_bib0054","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1093\/rheumatology\/kew196","article-title":"Autoantibodies against a complement component 1 q subcomponent contribute to complement activation and recurrent thrombosis\/pregnancy morbidity in anti-phospholipid syndrome","volume":"55","author":"Oku","year":"2016","journal-title":"Rheumatol. Oxf. Engl."},{"key":"10.1016\/j.imlet.2026.107148_bib0055","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1182\/blood.2019003863","article-title":"Complement activity and complement regulatory gene mutations are associated with thrombosis in APS and CAPS","volume":"135","author":"Chaturvedi","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.imlet.2026.107148_bib0056","doi-asserted-by":"crossref","first-page":"1522","DOI":"10.3390\/biom13101522","article-title":"The Molecular Mechanisms of Complement Receptor 1-It Is Complicated","volume":"13","author":"Hardy","year":"2023","journal-title":"Biomolecules"},{"key":"10.1016\/j.imlet.2026.107148_bib0057","doi-asserted-by":"crossref","unstructured":"N. Ranjan, M. Cole, G.F. Gerber, M.A. Crowther, E.M. Braunstein, D. Flores-Guerrero, K. Haddaway, A. Reed, M.B. Streiff, K.R. McCrae, M. Petri, S. Chaturvedi, R.A. Brodsky, Genetic and epigenetic dysregulation of CR1 is associated with catastrophic antiphospholipid syndrome (CAPS), medRxiv (2025) 2025.05.01.25326429. https:\/\/doi.org\/10.1101\/2025.05.01.25326429.","DOI":"10.1101\/2025.05.01.25326429"},{"key":"10.1016\/j.imlet.2026.107148_bib0058","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-018-35034-x","article-title":"Differences in plasma fibrin clot composition in patients with thrombotic antiphospholipid syndrome compared with venous thromboembolism","volume":"8","author":"Stachowicz","year":"2018","journal-title":"Sci. Rep."},{"key":"10.1016\/j.imlet.2026.107148_bib0059","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1038\/s41584-018-0032-6","article-title":"Obstetric and vascular antiphospholipid syndrome: same antibodies but different diseases?","volume":"14","author":"Meroni","year":"2018","journal-title":"Nat. Rev. Rheumatol."},{"key":"10.1016\/j.imlet.2026.107148_bib0060","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1182\/blood-2015-09-672139","article-title":"Complement activation in antiphospholipid syndrome and its inhibition to prevent rethrombosis after arterial surgery","volume":"127","author":"Meroni","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.imlet.2026.107148_bib0061","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1177\/096120339600500306","article-title":"Libman-Sacks endocarditis in the antiphospholipid syndrome: immunopathologic findings in deformed heart valves","volume":"5","author":"Ziporen","year":"1996","journal-title":"Lupus"},{"key":"10.1016\/j.imlet.2026.107148_bib0062","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1191\/096120399678840873","article-title":"Increased endothelial cell expression of alpha3beta1 integrin in cardiac valvulopathy in the primary (Hughes) and secondary antiphospholipid syndrome","volume":"8","author":"Afek","year":"1999","journal-title":"Lupus"},{"key":"10.1016\/j.imlet.2026.107148_bib0063","first-page":"keae397","article-title":"Kidney whole-transcriptome profiling in primary antiphospholipid syndrome reveals complement, interferons and NETs-related gene expression","author":"Tektonidou","year":"2024","journal-title":"Rheumatology"},{"key":"10.1016\/j.imlet.2026.107148_bib0064","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1016\/j.autrev.2015.01.008","article-title":"Histopathology in the placentae of women with antiphospholipid antibodies: a systematic review of the literature","volume":"14","author":"Viall","year":"2015","journal-title":"Autoimmun. Rev."},{"key":"10.1016\/j.imlet.2026.107148_bib0065","doi-asserted-by":"crossref","DOI":"10.1111\/aji.13185","article-title":"Complement activation in the plasma and placentas of women with different subsets of antiphospholipid syndrome","volume":"82","author":"Scambi","year":"2019","journal-title":"Am. J. Reprod. Immunol."},{"key":"10.1016\/j.imlet.2026.107148_bib0066","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/j.kint.2024.05.015","article-title":"The role of complement in kidney disease: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference","volume":"106","author":"Vivarelli","year":"2024","journal-title":"Kidney Int"},{"key":"10.1016\/j.imlet.2026.107148_bib0067","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1161\/01.CIR.97.9.900","article-title":"Differential Effects of Anti\u2013\u03b22-Glycoprotein I Antibodies on Endothelial Cells and on the Manifestations of Experimental Antiphospholipid Syndrome","volume":"97","author":"George","year":"1998","journal-title":"Circulation"},{"key":"10.1016\/j.imlet.2026.107148_bib0068","doi-asserted-by":"crossref","first-page":"1964","DOI":"10.1182\/blood-2004-05-1708","article-title":"Annexin A2 mediates endothelial cell activation by antiphospholipid\/anti-beta2 glycoprotein I antibodies","volume":"105","author":"Zhang","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.imlet.2026.107148_bib0069","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1056\/NEJMoa1312890","article-title":"Inhibition of the mTORC pathway in the antiphospholipid syndrome","volume":"371","author":"Canaud","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.imlet.2026.107148_bib0070","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCULATIONAHA.125.073552","article-title":"Microvascular endothelial cells license APS vasculopathy through YAP1- and CCN2-mediated signaling","author":"Shi","year":"2025","journal-title":"Circulation"},{"key":"10.1016\/j.imlet.2026.107148_bib0071","doi-asserted-by":"crossref","DOI":"10.1016\/j.autrev.2023.103274","article-title":"Interaction between endothelial cell-derived extracellular vesicles and monocytes: a potential link between vascular thrombosis and pregnancy-related morbidity in antiphospholipid syndrome","volume":"22","author":"\u00c1lvarez","year":"2023","journal-title":"Autoimmun. Rev."},{"key":"10.1016\/j.imlet.2026.107148_bib0072","doi-asserted-by":"crossref","first-page":"3962","DOI":"10.1182\/blood.V99.11.3962","article-title":"Interaction of endothelial microparticles with monocytic cells in vitro induces tissue factor\u2013dependent procoagulant activity","volume":"99","author":"Sabatier","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.imlet.2026.107148_bib0073","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.thromres.2017.06.014","article-title":"A novel 2-stage approach that detects complement activation in patients with antiphospholipid antibody syndrome","volume":"156","author":"Rand","year":"2017","journal-title":"Thromb. Res."},{"key":"10.1016\/j.imlet.2026.107148_bib0074","doi-asserted-by":"crossref","first-page":"2165","DOI":"10.1084\/jem.20061022","article-title":"Complement activation induces dysregulation of angiogenic factors and causes fetal rejection and growth restriction","volume":"203","author":"Girardi","year":"2006","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.imlet.2026.107148_bib0075","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1182\/bloodadvances.2018017095","article-title":"Complement C5 but not C3 is expendable for tissue factor activation by cofactor-independent antiphospholipid antibodies","volume":"2","author":"M\u00fcller-Calleja","year":"2018","journal-title":"Blood Adv."},{"key":"10.1016\/j.imlet.2026.107148_bib0076","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1177\/0961203307080224","article-title":"Impaired endothelial function and increased carotid intima-media thickness in association with elevated von Willebrand antigen level in primary antiphospholipid syndrome","volume":"16","author":"Der","year":"2007","journal-title":"Lupus"},{"key":"10.1016\/j.imlet.2026.107148_bib0077","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1136\/ard.62.7.607","article-title":"Increased carotid artery intima-media thickness may be associated with stroke in primary antiphospholipid syndrome","volume":"62","author":"Medina","year":"2003","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.imlet.2026.107148_bib0078","doi-asserted-by":"crossref","first-page":"e47","DOI":"10.1016\/j.ddmec.2011.12.002","article-title":"New insights into the molecular basis of the antiphospholipid syndrome","volume":"8","author":"Mineo","year":"2011","journal-title":"Drug Discov. Today Dis. Mech."},{"key":"10.1016\/j.imlet.2026.107148_bib0079","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1172\/JCI39828","article-title":"Antiphospholipid antibodies promote leukocyte-endothelial cell adhesion and thrombosis in mice by antagonizing eNOS via \u03b22GPI and apoER2","volume":"121","author":"Ramesh","year":"2011","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.imlet.2026.107148_bib0080","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.1016\/j.autrev.2017.09.012","article-title":"Neutrophil extracellular traps (NETs) in autoimmune diseases: a comprehensive review","volume":"16","author":"Lee","year":"2017","journal-title":"Autoimmun. Rev."},{"key":"10.1016\/j.imlet.2026.107148_bib0081","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1007\/s00281-022-00916-w","article-title":"Mechanisms of immunothrombosis and vasculopathy in antiphospholipid syndrome","volume":"44","author":"Knight","year":"2022","journal-title":"Semin. Immunopathol."},{"key":"10.1016\/j.imlet.2026.107148_bib0082","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1186\/s12920-022-01222-y","article-title":"Co-expression analysis to identify key modules and hub genes associated with COVID-19 in platelets","volume":"15","author":"Alarabi","year":"2022","journal-title":"BMC Med. Genomics"},{"key":"10.1016\/j.imlet.2026.107148_bib0083","article-title":"Antiphospholipid syndrome and catastrophic antiphospholipid syndrome: a comprehensive review of pathogenesis, clinical features, and management strategies","volume":"16","author":"Parepalli","year":"2024","journal-title":"Cureus"},{"key":"10.1016\/j.imlet.2026.107148_bib0084","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0060352","article-title":"Determining the population frequency of the CFHR3\/CFHR1 deletion at 1q32","volume":"8","author":"Holmes","year":"2013","journal-title":"PloS One"},{"key":"10.1016\/j.imlet.2026.107148_bib0085","first-page":"keae178","article-title":"Can complement activation be the missing link in antiphospholipid syndrome?","author":"Venturelli","year":"2024","journal-title":"Rheumatol. Oxf. Engl."},{"key":"10.1016\/j.imlet.2026.107148_bib0086","doi-asserted-by":"crossref","first-page":"J209","DOI":"10.1016\/j.jaut.2011.11.009","article-title":"Anti-phospholipid induced murine fetal loss: novel protective effect of a peptide targeting the \u03b22 glycoprotein I phospholipid-binding site. Implications for human fetal loss","volume":"38","author":"de la Torre","year":"2012","journal-title":"J. Autoimmun."},{"key":"10.1016\/j.imlet.2026.107148_bib0087","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1136\/annrheumdis-2013-204838","article-title":"Morbidity and mortality in the antiphospholipid syndrome during a 10-year period: a multicentre prospective study of 1000 patients","volume":"74","author":"Cervera","year":"2015","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.imlet.2026.107148_bib0088","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1007\/s11926-013-0324-4","article-title":"Inhibition of nitric oxide and antiphospholipid antibody-mediated thrombosis","volume":"15","author":"Mineo","year":"2013","journal-title":"Curr. Rheumatol. Rep."},{"key":"10.1016\/j.imlet.2026.107148_bib0089","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/j.autrev.2007.01.003","article-title":"Cardiac manifestations in antiphospholipid syndrome","volume":"6","author":"Solt\u00e9sz","year":"2007","journal-title":"Autoimmun. Rev."},{"key":"10.1016\/j.imlet.2026.107148_bib0090","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1007\/s00296-025-06050-8","article-title":"Antiphospholipid antibodies and atherosclerotic vascular disease: recent advances","volume":"45","author":"Undas","year":"2025","journal-title":"Rheumatol. Int."},{"key":"10.1016\/j.imlet.2026.107148_bib0091","doi-asserted-by":"crossref","first-page":"3408","DOI":"10.1093\/rheumatology\/keab882","article-title":"Atherosclerosis progression in antiphospholipid syndrome is comparable to diabetes mellitus: a 3\u2009year prospective study","volume":"61","author":"Evangelatos","year":"2022","journal-title":"Rheumatology"},{"key":"10.1016\/j.imlet.2026.107148_bib0092","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1093\/rheumatology\/keae097","article-title":"Seven-year follow-up atherosclerotic plaque progression in patients with antiphospholipid syndrome versus diabetes mellitus and healthy controls","volume":"64","author":"Evangelatos","year":"2025","journal-title":"Rheumatology"},{"key":"10.1016\/j.imlet.2026.107148_bib0093","doi-asserted-by":"crossref","first-page":"3408","DOI":"10.1093\/rheumatology\/keab882","article-title":"Atherosclerosis progression in antiphospholipid syndrome is comparable to diabetes mellitus: a 3\u2009year prospective study","volume":"61","author":"Evangelatos","year":"2022","journal-title":"Rheumatology"},{"key":"10.1016\/j.imlet.2026.107148_bib0094","doi-asserted-by":"crossref","first-page":"2292","DOI":"10.1182\/blood-2009-04-213520","article-title":"Hydroxychloroquine protects the annexin A5 anticoagulant shield from disruption by antiphospholipid antibodies: evidence for a novel effect for an old antimalarial drug","volume":"115","author":"Rand","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.imlet.2026.107148_bib0095","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1002\/art.42459","article-title":"Antiphospholipid Syndrome Alliance for Clinical Trials and International Networking (APS ACTION), Fluctuation of Anti\u2013Domain 1 and Anti\u2013\u03b22-Glycoprotein I antibody titers over time in patients with persistently positive antiphospholipid Antibodies","volume":"75","author":"Chighizola","year":"2023","journal-title":"Arthritis Rheumatol."},{"key":"10.1016\/j.imlet.2026.107148_bib0096","first-page":"139","article-title":"Immunomodulatory effects of HMG-CoA reductase inhibitors","volume":"51","author":"Danesh","year":"2003","journal-title":"Arch. Immunol. Ther. Exp. (Warsz.)"},{"key":"10.1016\/j.imlet.2026.107148_bib0097","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1177\/10892532241249782","article-title":"Management of anticoagulation and antifibrinolytics in catastrophic antiphospholipid syndrome","volume":"28","author":"Park","year":"2024","journal-title":"Semin. Cardiothorac. Vasc. Anesth."},{"key":"10.1016\/j.imlet.2026.107148_bib0098","doi-asserted-by":"crossref","DOI":"10.1177\/10760296241306751","article-title":"Key issues at the forefront of diagnosis and testing for antiphospholipid syndrome","volume":"30","author":"Qiao","year":"2024","journal-title":"Clin. Appl. Thromb."},{"key":"10.1016\/j.imlet.2026.107148_bib0099","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1111\/jth.15158","article-title":"Trial of Rivaroxaban in AntiPhospholipid Syndrome (TRAPS): Two-year outcomes after the study closure","volume":"19","author":"Pengo","year":"2021","journal-title":"J. Thromb. Haemost. JTH"},{"key":"10.1016\/j.imlet.2026.107148_bib0100","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.jacc.2022.10.008","article-title":"Direct oral anticoagulants vs vitamin K antagonists in patients with antiphospholipid syndromes: meta-analysis of randomized trials","volume":"81","author":"Khairani","year":"2023","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.imlet.2026.107148_bib0101","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.semarthrit.2018.11.005","article-title":"Secondary thrombotic microangiopathy in systemic lupus erythematosus and antiphospholipid syndrome, the role of complement and use of eculizumab: Case series and review of literature","volume":"49","author":"Kello","year":"2019","journal-title":"Semin. Arthritis Rheum."},{"key":"10.1016\/j.imlet.2026.107148_bib0102","doi-asserted-by":"crossref","first-page":"2179","DOI":"10.1111\/ajt.12319","article-title":"Eculizumab improves posttransplant thrombotic microangiopathy due to antiphospholipid syndrome recurrence but fails to prevent chronic vascular changes","volume":"13","author":"Canaud","year":"2013","journal-title":"Am. J. Transplant. Off. J. Am. Soc. Transplant. Am. Soc. Transpl. Surg."},{"key":"10.1016\/j.imlet.2026.107148_bib0103","doi-asserted-by":"crossref","first-page":"2473","DOI":"10.1182\/blood.2020007499","article-title":"Patients with refractory catastrophic antiphospholipid syndrome respond inconsistently to eculizumab","volume":"136","author":"Yelnik","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.imlet.2026.107148_bib0104","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1016\/S0140-6736(23)01524-6","article-title":"Complement in human disease: approved and up-and-coming therapeutics","volume":"403","author":"West","year":"2024","journal-title":"Lancet Lond. Engl."},{"key":"10.1016\/j.imlet.2026.107148_bib0105","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1016\/S0140-6736(23)01524-6","article-title":"Complement in human disease: approved and up-and-coming therapeutics","volume":"403","author":"West","year":"2024","journal-title":"Lancet Lond. Engl."},{"key":"10.1016\/j.imlet.2026.107148_bib0106","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1038\/s41584-021-00742-8","article-title":"Defibrotide inhibits NET-mediated thrombosis in APS models","volume":"18","author":"Onuora","year":"2022","journal-title":"Nat. Rev. Rheumatol."},{"key":"10.1016\/j.imlet.2026.107148_bib0107","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1016\/j.jtha.2022.12.002","article-title":"Targeting thromboinflammation in antiphospholipid syndrome","volume":"21","author":"Salet","year":"2023","journal-title":"J. Thromb. Haemost. JTH"},{"key":"10.1016\/j.imlet.2026.107148_bib0108","doi-asserted-by":"crossref","DOI":"10.1016\/j.rpth.2024.102327","article-title":"Bleeding events in thrombotic antiphospholipid syndrome: prevalence, severity, and associated damage accrual","volume":"8","author":"Gaspar","year":"2024","journal-title":"Res. Pract. Thromb. Haemost."},{"key":"10.1016\/j.imlet.2026.107148_bib0109","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1097\/01.md.0000172074.53583.ea","article-title":"Long-term follow-up in 128 patients with primary antiphospholipid syndrome: do they develop lupus?","volume":"84","author":"G\u00f3mez-Puerta","year":"2005","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.imlet.2026.107148_bib0110","doi-asserted-by":"crossref","first-page":"2862","DOI":"10.1093\/rheumatology\/keae583","article-title":"ANA-positive versus ANA-negative Antiphospholipid Antibody-positive Patients: Results from the Antiphospholipid Syndrome Alliance for Clinical Trials and International Networking (APS ACTION) Clinical Database and Repository (\u201cRegistry\u201d)","volume":"64","author":"Cecchi","year":"2025","journal-title":"Rheumatology"},{"key":"10.1016\/j.imlet.2026.107148_bib0111","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.revmed.2011.10.008","article-title":"Anticorps antiphospholipides et h\u00e9mostase","volume":"33","author":"Masliah-Planchon","year":"2012","journal-title":"Rev. M\u00e9decine Interne"},{"key":"10.1016\/j.imlet.2026.107148_bib0112","doi-asserted-by":"crossref","first-page":"1490","DOI":"10.1182\/blood-2006-07-030148","article-title":"Correlation between antiphospholipid antibodies that recognize domain I of \u03b22-glycoprotein I and a reduction in the anticoagulant activity of annexin A5","volume":"109","author":"de Laat","year":"2006","journal-title":"Blood"}],"container-title":["Immunology Letters"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165247826000210?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165247826000210?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,16]],"date-time":"2026-03-16T13:43:06Z","timestamp":1773668586000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0165247826000210"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":112,"alternative-id":["S0165247826000210"],"URL":"https:\/\/doi.org\/10.1016\/j.imlet.2026.107148","relation":{},"ISSN":["0165-2478"],"issn-type":[{"value":"0165-2478","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Complement involvement in antiphospholipid syndrome","name":"articletitle","label":"Article Title"},{"value":"Immunology Letters","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.imlet.2026.107148","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier B.V. on behalf of European Federation of Immunological Societies.","name":"copyright","label":"Copyright"}],"article-number":"107148"}}